Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform
Key Highlights
- ➤USPTO issued Patent No. 12,797,335 covering Cingulate’s trimodal buspirone tablet formulation.
- ➤CTx-2103 targets once-daily anxiety treatment using three precisely timed buspirone releases.
- ➤Cingulate plans CTx-2103 development after CTx-1301 approval.
- ➤CTx-1301 NDA resubmission targeted between December 2026 and January 2026.
- ➤FDA issued CTx-1301 a Complete Response Letter on June 1, 2026.
Expert Statements
Shane J. Schaffer, Chairman and CEO of Cingulate
“Cingulate remains focused on advancing CTx-1301, our lead ADHD treatment candidate, toward NDA resubmission and commercialization in the second half of 2027, if approved. We believe CTx-2103 represents an attractive opportunity to build a pipeline of assets beyond ADHD with our proprietary PTR™ Platform. The issuance of this patent further strengthens the Company’s intellectual property portfolio. Following approval of CTx-1301, Cingulate anticipates initiating the development of CTx-2103”
KANSAS CITY, Kan., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,797,335, titled "Trimodal, Precision-Timed Release Tablet."
The newly issued patent covers a buspirone tablet formulation incorporating Cingulate's proprietary PTR™ technology, which is designed to release medication at three separate, predetermined times throughout the day from a single tablet. Buspirone is an FDA-approved treatment for anxiety disorders. The patented formulation supports the Company's development of CTx-2103 and further demonstrates the versatility and broader applicability of Cingulate's technology beyond its initial focus on ADHD.
Get started
Create a free account to read the full story.
